<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202819">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00449163</url>
  </required_header>
  <id_info>
    <org_study_id>20060042</org_study_id>
    <secondary_id>SCCC-2005145</secondary_id>
    <secondary_id>WIRB-20060252</secondary_id>
    <nct_id>NCT00449163</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer</brief_title>
  <official_title>Phase II Study of Avastin, Irinotecan, High Dose 24 Hour Continuous Intravenous Infusion of Floxuridine and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as irinotecan, floxuridine, and leucovorin, work
      in different ways to stop the growth of tumor cells, either by killing the cells or by
      stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor
      growth in different ways. Some block the ability of tumor cells to grow and spread. Others
      find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab
      may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving
      combination chemotherapy together with bevacizumab may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together
      with bevacizumab works in treating patients with stage IV colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine whether irinotecan hydrochloride, floxuridine, leucovorin calcium, and
           bevacizumab improves overall survival of patients with stage IV colorectal cancer.

      Secondary

        -  Estimate response rate (complete response and partial response), time to response, and
           progression-free survival of patients treated with this regimen.

        -  Estimate the resectability rate in patients treated with this regimen.

        -  Evaluate the safety and toxicity of this regimen.

        -  Assess the quality of life of patients treated with this regimen.

      OUTLINE: Patients receive bevacizumab IV over 90 minutes on days 1 and 22 and irinotecan
      hydrochloride IV over 90 minutes, leucovorin calcium IV over 24 hours, and high-dose
      floxuridine IV over 24 hours on days 1, 8, 22, and 29. Treatment repeats every 6 weeks in
      the absence of disease progression or unacceptable toxicity. Patients are evaluated after
      completion of every 2 courses of therapy. Patients whose disease is deemed operable at
      evaluation are referred to surgery.

      Patients complete a quality of life assessment at baseline, every 6 weeks during study
      treatment, and periodically at follow-up.

      After completion of study treatment, patients are followed every 3 months for 6 months,
      every 6 months for 1 year, and then annually thereafter.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated by University of Miami Institutional Review Board
  </why_stopped>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival up to 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients with overall survival times of up to 2 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate (Complete Response and Partial Response)</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Progression-free Survival in Months</measure>
    <time_frame>2 years</time_frame>
    <description>Median number of months subjects achieved progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>floxuridine</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the colon and/or rectum

          -  Stage IV disease

          -  Bidimensionally measurable disease

          -  CNS metastasis allowed provided radiotherapy has been completed

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-1 or Karnofsky PS 70-100%

          -  Life expectancy ≥ 2 months

          -  Absolute neutrophil count &gt; 1,000/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Creatinine ≤ 1.5 mg/dL

          -  Bilirubin ≤ 1.5 mg/dL

          -  AST ≤ 3 times upper limit of normal (5 times ULN if liver metastases are present)

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No other malignancy within the past 5 years

          -  No active infection

          -  No New York Heart Association class II-IV congestive heart failure

          -  No serious underlying medical illness

          -  No psychiatric condition or associated condition that would preclude study
             participation

          -  No uncontrolled hypertension

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No prior chemotherapy or radiotherapy for colorectal cancer, except for adjuvant
             chemotherapy or radiotherapy

          -  At least 8 weeks since prior surgery for colorectal cancer and recovered

          -  At least 30 days since prior investigational drugs

          -  No concurrent radiotherapy, hormonal therapy, or other chemotherapy or immunotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bach Ardalan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Miami Sylvester Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>B. Ardalan, M. Feagans, D. Mezentsev, C. Jones, P. R. Subbarayan, G. Walker, M. Sapp, K. Stephenson, J. Ness, D. Franceschi and A. Livingstone. Phase II study of bevacizumab (B), camptosar (I), high-dose 24-hour continuous intravenous infusion of floxuridine (F) and leucovorin (L) in patients with previously untreated metastatic colon cancer. (B-IFL). Journal of Clinical Oncology, Vol 27, No 15S (May 20 Supplement), 2009: e15114</citation>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 14, 2016</lastchanged_date>
  <firstreceived_date>March 15, 2007</firstreceived_date>
  <firstreceived_results_date>January 23, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 25 subjects were enrolled however; data were analyzed for only 22 of the subjects enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Combination Chemotherapy + Bevacizumab</title>
          <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="38" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival up to 2 Years</title>
        <description>Percentage of patients with overall survival times of up to 2 years</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy + Bevacizumab</title>
            <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival up to 2 Years</title>
          <description>Percentage of patients with overall survival times of up to 2 years</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="27" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate (Complete Response and Partial Response)</title>
        <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy + Bevacizumab</title>
            <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (Complete Response and Partial Response)</title>
          <description>Percentage of patients achieving complete response or partial response per RECIST criteria ver 1.0</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="43" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Progression-free Survival in Months</title>
        <description>Median number of months subjects achieved progression-free survival</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Combination Chemotherapy + Bevacizumab</title>
            <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival in Months</title>
          <description>Median number of months subjects achieved progression-free survival</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="8.4" lower_limit="8.4" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>irinotecan hydrochloride : adjuvant therapy : neoadjuvant therapy : floxuridine : leucovorin calcium : bevacizumab :</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Small Bowel Obstruction</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <description>Grade 4</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Port Site Thrombosis</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <description>Grade 3</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A total of 25 subjects were enrolled however; data were analyzed for 22 subjects only. Study was terminated early by the University of Miami Institutional Review Board.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Bach Ardalan MD</name_or_title>
      <organization>UM/Sylvester Comprehensive Cancer Center</organization>
      <phone>305-243-4909</phone>
      <email>bardalan@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
